[Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease].
| Autor: | Dzgoeva FU, Gatagonova TM, Bestaeva TL, Sopoev MIu, Bazaeva BG, Khamitsaeva OV |
|---|---|
| Jazyk: | ruština |
| Zdroj: | Terapevticheskii arkhiv [Ter Arkh] 2014; Vol. 86 (6), pp. 63-9. |
| Abstrakt: | Aim: To study the role of the bone mineral metabolic mediators osteoprotegerin (OPG) and fibroblast growth factor 23 (FGF-23) in the mechanisms of cardiovascular events (CVEs) in chronic kidney disease (CKD). Subjects and Methods: Sixty-eight patients (30 men and 38 women) aged 38 to 64 years (mean age 49 +/- 6.3 years) with Stages III-VD CKD were examined. The stages of CKD were determined in accordance with the NKF-K/DOQI guidelines; glomerular filtration rate was calculated using the CKD-EPI formula. Serum OPG and FGF-23 were examined in all the patients, by applying commercial enzyme immunoassay kits. Doppler echocardiography was performed to evaluate the morphofunctional state of the left ventricle (LV). Results: As renal failure progressed from Stage III to Stage VD CKD, the examined patients had higher serum OPG and FGF-23 concentrations. The levels of OPG and FGF-23 and the morphofunctional indicators of LV lesion, blood pressure, and anemia showed a strong direct correlation that preserved its significance in analyzing the factors in question in relation to the function of the kidneys and the pattern of cardiovascular system lesion. Conclusion: The morphogenetic proteins OPG and FGF-23 seem to play a significant role not only in bone remodeling processes, but also in the development of CVEs in CKD. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|